In patients who transitioned from injected SRLs to once-daily oral PALSONIFY, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

The level of insulin-like growth factor 1 (IGF-I) is influenced by many factors but, as detailed here, IGF-I measurements are useful to screen for growth hormone deficiencies in children and young ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, ...

Tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog, has garnered significant attention in scientific ...

An example of a clinically relevant biomarker that has been targeted by MALDImmunoassays is insulin-like growth factor 1 (IGF1). (9, 18) IGF1, a 7.65 kDa polypeptide hormone, is the main mediator of ...

Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes.

ABSTRACT Objects To compare insulin resistance (IR) and metabolic aspects of patients with neurofibromatosis type 1 (NF1) and individuals without the disease. Subjects and methods Forty patients with ...

Background/aims The aim of this study was to assess the effect of functional ENPP1(ectoenzyme nucleotide pyrophosphate phosphodiesterase 1)/PC-1 (plasma cell antigen-1) and IRS-1 (insulin receptor ...

Insulin and IGF-1 have specific and physiological vascular actions in humans and experimentally derived animals and cause an increase in SMBF and a decrease in vascular resistance.

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates ...